Abstract-Despite an extensive diagnostic workup, some cases of acute transverse myelitis (ATM) remain of unknown etiology and have been referred to as "idiopathic" by the Transverse Myelitis Consortium group. In a retrospective study of 288 patients with ATM, 45 cases (15.6%) met the criteria for idiopathic ATM. The patients formed a relatively homogeneous group in terms of clinical and MRI data, but the prognosis was highly variable.
Methods. Nine neurologic departments agreed to participate in this study. For each center, patients were retrospectively classified according to the following categories: systemic diseases, spinal cord infarct, MS, neuromyelitis optica, infectious/ parainfectious diseases, and idiopathic ATM after previous classifications. 1, 2 As proposed by the Consortium group, patients with a spinal cord MRI suggesting spinal cord infarct (arterial territory on spinal cord MRI or sudden deficit in less than 4 hours) were included in the spinal cord infarct group. Infectious/parainfectious disease, systemic disease, and MS were diagnosed after an extensive workup. 1 Systemic disease diagnosis was performed following standard rheumatologic criteria as previously described. 1 A CSF analysis was performed in all patients. We also performed visual evoked potentials (VEPs) and a chest x-ray. We performed a salivary gland biopsy if there were clinical or biologic signs suggestive of sicca syndrome. We excluded patients with a history of irradiation.
Details of the etiologies for each center are summarized in table 2.
We then retrospectively studied the 45 cases of idiopathic ATM diagnosed among the entire cohort of 288 ATM patients (15.6%). Patients were considered as having severe initial symptoms if they were unable to walk or had urinary incontinence or required catheterization. A statistical comparison ( 2 , unpaired Wilcoxon or Pearson tests for quantitative and qualitative variables) was performed between the group with a poor outcome (death or inability to walk) and the group with a good outcome (partial or complete recovery, ability to walk with or without aid, or isolated urinary disturbances) after the initial attack and at the end of the follow-up. The main clinical and laboratory results are  shown in table 3 .
Results.
The T2-weighted hypersignal on spinal cord MRI extended to more than two vertebral segments in all but 2 patients (95.2%). Brain MRI was performed in 38 patients and was always normal. VEPs were normal in all patients. CSF showed increased cell count and protein level in 19 cases (42.2%) and 9 cases (20%), respectively, with a mean of 24.9 Ϯ 52.4 cells (predominantly lymphocytes) and a mean protein level of 0.53 Ϯ 0.31. Oligoclonal bands were found in 8 patients (17.7%). According to the Consortium criteria, 31 patients (68.9%) had definite idiopathic ATM, and 14 patients (31.1%) had possible idiopathic ATM.
All but 3 patients were treated with corticosteroid (1 g/d IV for 3 days). None of the patients received oral prednisolone. In cases of either a poor response to steroids or a relapse, this treatment was followed by cyclophosphamide (8 patients), azathioprine (4 patients), and IV immunoglobulins (4 patients) after a mean delay of 45.6 (Ϯ 18.2) days. Three months after the first event, 13 patients had a poor outcome and 32 had a good outcome, but 3 of the latter presented severe relapses and had a poor outcome at the end of the follow-up. One patient died during the follow-up, and 15 patients (33.3%) had a poor outcome (inability to walk).
Although the treatments were not randomized and were only given to 16 patients (10 in the "severe initial symptoms" group and six in the other group), they did not seem to have a beneficial effect on clinical outcome at the end of the study, because only four patients improved after immunosuppressive drugs (two in the group with a good outcome and two in the group with a poor outcome). Two patients were treated with IV immunoglobulin, one with cyclophosphamide and one with azathioprine. The time from disease onset to the initiation of treatment did not influence the response. The four patients with an improvement were treated 41.5 Ϯ 12.5 days after disease onset compared with 47.2 Ϯ 30.5 days in the group without improvement (difference not significant).
When we compared the poor-outcome group (n ϭ 16) and the good-outcome group (n ϭ 29) after a mean follow-up of 3.6 Ϯ 3.1 years, we did not find any differences in terms of sex, age, or clinical MRI or CSF data (including the comparison between the relapsing and the nonrelapsing group; see table 3). Severe initial symptoms suggesting spinal shock were the only, though highly predictable, cri- HTLV-I ϭ human T-cell lymphotrophic virus type I; MS ϭ multiple sclerosis. teria for a poor outcome at the end of the follow-up (p Ͻ 0.001). In 11 (24.4%) patients, the myelitis had a relapsing course with a mean of 0.53 relapses per year, without any differences between the two groups (see table 3 ). At the end of the follow-up, none of the patients had new symptoms suggestive of MS.
Discussion. Our study shows that the proposed criteria for idiopathic ATM lead to a relatively homogenous group in terms of clinical and MRI data but that, even if severe initial symptoms are correlated with a poor prognosis, the outcome remains unpredictable. There is therefore a need for serum or CSF markers to identify patients with a high risk of poor outcome before therapeutic trials in idiopathic ATM can be performed. Several studies have looked for CSF markers (14-3-3 protein, neuron specific enolase, and others) in acute myelopathies, but they did not focus on idiopathic ATM, and the results were contradictory. [3] [4] [5] In the current study, we found that severe initial symptoms suggesting spinal shock were highly predictive of a poor outcome, in accordance with previous studies on ATM (which did not distinguish between the various etiologies). 6, 7 We found that approximately two-thirds of the patients in our study had definite idiopathic ATM; the remainder were considered as having possible idiopathic ATM because of the lack of inflammatory signs in CSF or on MRI. 2 However, we decided not to exclude these patients, following the discussion of the expert panel of the Transverse Myelitis Consortium group, which suggested that they should be included as having possible idiopathic ATM.
We found gadolinium enhancement in only 38% of cases, but this result was consistent with that of a previous study that found that 47% of spinal cord MRIs were gadolinium enhanced in a subgroup of 15 cases of idiopathic ATM. 8 We did not observe any difference between the definite and possible idiopathic ATM groups, especially regarding the outcome. This result suggests that both possible and definite idiopathic ATM patients could be included in clinical and therapeutic trials.
Although our study was not randomized and was not designed to test therapeutic efficacy, it was surprising to observe the absence of any beneficial effect of immunosuppressive drugs in 12 of the 16 treated patients. The absence of effect may have been due to the delay between the onset of symptoms and the start of these treatments. It would be interesting to test the effect of immunosuppressive drugs associated with a high dose of corticosteroids within the week after the onset of symptoms in cases where these are severe (e.g., spinal shock symptoms). It would also be interesting to test the effectiveness of other forms of therapy, such as plasma exchange and CSF cytapheresis, as proposed in several cases of acute disseminated encephalomyelitis or GuillainBarré syndrome. 9, 10 However, the low prevalence of idiopathic ATM makes randomized trials difficult and underlines the need for multicenter studies.
